Filing Signals

Source: SEC EDGAR Compiled 2026-11-14 10:32 UTC 23 automated checks passing

← All events

RetinalGenix Technologies Inc.

CIK 1836295 RTGN·Medical Instruments · All EDGAR filings ↗

Progression

  1. Finance chief departure 8-K
  2. Late filing NT 10-K +4d
  3. Auditor change 8-K +107d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Late filing Filing comparison

RetinalGenix Technologies Inc. told the SEC it could not file its quarterly report on time

Does not expect a significant change in results. Filed 1 day before the statutory due date.

NARRATIVE The Company is unable to file its Quarterly Report on Form 10Q ended September 30, 2026 by November 16, 2026 without unreasonable effort or expense. The Company requires additional time to finalize its financial statements for such quarterly period.
Evidence
Anticipates significant change
No
Days past due date
-1
Other periodic reports filed
Yes
Routine
Yes
Severity
normal
Source
Form 12b-25 (notification of late filing)
Stated reason
NARRATIVE The Company is unable to file its Quarterly Report on Form 10Q ended September 30, 2026 by November 16, 2026 without unreasonable effort or expense. The Company requires additional time to finalize its financial statements for such quarterly period.
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Auditor change high SEC item code

RetinalGenix Technologies Inc.'s auditor resigned

The auditor resigned. not stated → Vilki & Co No disagreements disclosed.

Evidence
Direction
resigned
Direction label
The auditor resigned
Disagreements disclosed
No
Item code
4.01
Item title
Changes in Registrant's Certifying Accountant
Severity
high
Source
SEC 8-K item code
Successor auditor
Vilki & Co
Successor tier
other
Tier downgrade
No
Why
The company's independent registered accounting firm changed.

Source filing ↗

Late filing Filing comparison

RetinalGenix Technologies Inc. told the SEC it could not file its quarterly report on time

Does not expect a significant change in results. Filed on the statutory due date.

NARRATIVE The Company is unable to file its Quarterly Report on Form 10Q ended March 31, 2026 by May 15, 2026 without unreasonable effort or expense. The Company requires additional time to finalize its financial statements for such quarterly period.
Evidence
Anticipates significant change
No
Days past due date
0
Routine
Yes
Severity
normal
Source
Form 12b-25 (notification of late filing)
Stated reason
NARRATIVE The Company is unable to file its Quarterly Report on Form 10Q ended March 31, 2026 by May 15, 2026 without unreasonable effort or expense. The Company requires additional time to finalize its financial statements for such quarterly period.
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Late filing elevated Filing comparison

RetinalGenix Technologies Inc. told the SEC it could not file its annual report on time

Does not expect a significant change in results. Filed 1 day before the statutory due date.

NARRATIVE The Company is unable to file its Annual Report on Form 10K ended December 31, 2025 by March 31, 2026 without unreasonable effort or expense. The Company requires additional time to finalize its financial statements for such fiscal year ended December 31, 2025.
Evidence
Anticipates significant change
No
Days past due date
-1
Routine
No
Severity
elevated
Source
Form 12b-25 (notification of late filing)
Stated reason
NARRATIVE The Company is unable to file its Annual Report on Form 10K ended December 31, 2025 by March 31, 2026 without unreasonable effort or expense. The Company requires additional time to finalize its financial statements for such fiscal year ended December 31, 2025.
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Finance chief departure Filing comparison

RetinalGenix Technologies Inc.'s Chief Financial Officer departed and a successor was named

Evidence
Interim only
No
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
normal
Source
SEC 8-K item code
Successor named
Yes
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗